Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT
Autor: | Dick Bezemer, Marielle G. van Pampus, Marion E. van Hoorn, William M. Hague, Johanna I.P. de Vries |
---|---|
Přispěvatelé: | Obstetrics and gynaecology, Epidemiology and Data Science, MOVE Research Institute, ICaR - Ischemia and repair |
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
030204 cardiovascular system & hematology
0302 clinical medicine Recurrence CLASSIFICATION CRITERIA Netherlands Randomised controlled trial Aspirin education.field_of_study 030219 obstetrics & reproductive medicine Obstetrics and Gynecology Antiphospholipid Syndrome Intention to Treat Analysis Treatment Outcome PREGNANCY Infant Small for Gestational Age Antibodies Antiphospholipid Premature Birth Drug Therapy Combination Female medicine.drug Adult medicine.medical_specialty medicine.drug_class HELLP syndrome Population INTERNATIONAL CONSENSUS STATEMENT Low molecular weight heparin Gestational Age CONTROLLED-TRIAL 03 medical and health sciences Young Adult Fibrinolytic Agents Antiphospholipid syndrome Internal medicine medicine Humans Low-molecular-weight heparin education Gynecology Sweden Pregnancy Eclampsia business.industry Antiphospholipid antibodies Australia Infant Newborn WORKSHOP Hypertension Pregnancy-Induced Heparin Low-Molecular-Weight medicine.disease Pregnancy Trimester First Reproductive Medicine UPDATE business Pre-eclampsia Fibrinolytic agent |
Zdroj: | European Journal of Obstetrics and Gynecology and Reproductive Biology, 197, 168-173. Elsevier Ireland Ltd van Hoorn, M E, Hague, W M, van Pampus, M G, Bezemer, D & de Vries, J I P 2016, ' Low-molecular-weight heparin and aspirin in the prevention of recurrent early-onset pre-eclampsia in women with antiphospholipid antibodies: the FRUIT-RCT ', European Journal of Obstetrics and Gynecology and Reproductive Biology, vol. 197, pp. 168-173 . https://doi.org/10.1016/j.ejogrb.2015.12.011 European journal of obstetrics gynecology and reproductive biology, 197, 168-173. ELSEVIER SCIENCE BV |
ISSN: | 0301-2115 |
Popis: | To examine whether combined treatment with low-molecular-weight heparin (LMWH) and aspirin reduces recurrent hypertensive disorders of pregnancy (HD: pre-eclampsia, eclampsia or HELLP syndrome) in women with antiphospholipid antibodies (aPLA) and a previous delivery for HD and/or small-for-gestational-age (SGA) birthweight before 34 weeks gestation.This multicentre randomised controlled trial was performed between December 2000 and December 2009. Women were recruited from all eight university and six non-university/teaching hospitals in The Netherlands, two university hospitals in Australia and one university hospital in Sweden. Thirty two women with a previous delivery34 weeks gestation with HD and/or SGA and aPLA were included before 12 weeks gestation. The intervention was daily LMWH with aspirin or aspirin alone.recurrent HD onset34 weeks and recurrent HD irrespective of gestational age. Analysis by intention-to-treat.After an interim analysis, recruitment was ceased: accrual was low and the incidence of recurrent HD was far lower (3%) than expected (60%). The final analysis, performed on 32 women, shows no difference in the primary outcomes (LMWH and aspirin 0/16 versus aspirin only 1/16, risk difference 6.25% [CI -17 to 27%] for recurrent HD onset34 weeks and 0/16 for LMWH and aspirin versus 2/16 for aspirin only, risk difference 12.5% [CI -15 to 35%] for HD irrespective of gestational age).In this population of women with aPLA, who had previously had an early delivery for HD and/or SGA prior to 34 weeks gestation, combined LMWH and aspirin treatment started before 12 weeks gestation in a subsequent pregnancy did not show reduction of onset of recurrent HD either34 weeks gestation or irrespective of gestational age, compared with aspirin alone. |
Databáze: | OpenAIRE |
Externí odkaz: |